Key Takeaways Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

Allurion's flagship offering, the Allurion Program, integrates the Allurion Gastric Balloon, a swallowable device that aids in weight loss without the need for a surgical procedure. The program ...

Allurion cited prior studies demonstrating that its gastric balloon, combined with its Virtual ... in its July 2024 offering to $6.00 per share after obtaining shareholder approval.

Allurion's flagship offering, the Allurion Program, integrates the Allurion Gastric Balloon, a swallowable device that aids in weight loss without the need for a surgical procedure. The program also ...

Allurion Technologies announced it would begin a study to see if its gastric balloon, combined with popular ... investors something to cheer about after they watched the shares sink rapidly ...